🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Humbled to share my research on post-progression therapies for BRCA-related pancreatic cancer got accepted for presentation at #ASCO24! Immense gratitude to my mentors Syed Kazmi, M.D. Tim Brown, MD MSCE Salwan Al Mutar MD MS Kim Reiss Binder (Kim Reiss) for their unwavering support! UTSW Simmons Cancer Center Aga Khan University

TransMet #ASCO24 game-changer ➡️definitively unresectable CRC LM ➡️chemo vs chemo &transplant ➡️heavily pre treated ➡️highly selected 👇🏻note %RASWT and left sided ➡️v impressive 5 yr OS 57 v13% ITT ➡️many recurrences rescued

#ASCO24 CRC Orals: Completely agree with Kristen Ciombor- Don’t want to see any more neoadj dMMR IO trials reporting path responses (non validated as a relevant surrogate endpoint for colon relapse) with short median follow ups. Time to set the bar at DFS to report, IMO

We are so proud to be part of “House of Lynn” Robin Zon, MD, FACP, FASCO ASCO #ASCO24 Grateful to have fantastic leadership in the house Angie DeMichele, MD, MSCE, FASCO Penn Medicine - Abramson Cancer Center Penn Medicine Penn Medicine MD OncoAlert Penn Cancer Innovation

Seven years ago, a grant from the wonderful Conquer Cancer, the ASCO Foundation helped launch my career. I am forever grateful. It cannot be overstated how important such funding can be for an early investigator. Support!!!! Eric J. Small, MD, FASCO Neelima Denduluri

Good news for drug development: still ok to use either regimen as the backbone for front line trials that include chemo. But bottom line? Need better drugs.

There are so much more we can learn from these trials (GIANT, PASS-01, RTOG-0848) and each of the patient participants. Efrat Dotan MD Jennifer Knox Grainne O'Kane Karyn Goodman, MD, MS thanks you to chairs of the session! Kim Reiss Binder (Kim Reiss) Kristen Spencer

Read the review from the October issue—KRAS-Driven #Tumorigenesis and KRAS-Driven Therapy in #PancreaticAdenocarcinoma, by Minh T. Than, Mark O'Hara, Ben Stanger, and Kim Reiss Binder (Kim Reiss). bit.ly/4eFjioa Penn Medicine Penn Medicine - Abramson Cancer Center #KRAS

This trial is being run by Eileen M O’Reilly & Kim Reiss Binder (Kim Reiss) #pancchat

First clinical data of Revolution Medicines KRAS G12D inhibitor RMC-9805 in #PancreaticCancer presented by David S. Hong MD MD Anderson Cancer Center globenewswire.com/en/news-releas… 30% objective response rate, 80% disease control rate at 1200mg daily dose. #ENA2024

If you're building your #ASCO25 schedule, don't forget to include our session into your planner. See you there!

A plug for our Alliance for Clinical Trials in Oncology trial for patients with BRCA1/2 or PALB2 mutant pancreas cancer! #NCTN #PancChat Eileen M O’Reilly Kim Reiss Binder (Kim Reiss) Mike Pishvaian Efrat Dotan MD Hagen Kennecke Anirban Maitra Sharlene Gill, MD, MPH, MBA, FASCO PanCAN BasserBRCA @FacingOurRisk

Remote assessment of patients on clinical trial, via telemedicine, opens the door to more widespread enrollment from patients in rural areas and more. APOLLO trial in pancreatic cancer is the first NCI-funded trial to allow this -Shaalan Beg MD MBA FASCO #AACR25 Plenary

BREAKWATER shows that 1L EC+FOLFOX results in mPFS 12.8m and mOS 30.3m!! 🥹🥲 That mOS far exceeded my greatest hope for this study. A great turning point for a bad actor 🙌👊🏻 #ASCO25

MATTERHORN has dropped. Improved EFS. OS looking good but not analyzed officially. Durva and FLOT new SOC for resectable gastric/GEJ? Likely

New standard of care for stage III, improved DFS with the addition of atezolizumab to FOLfOX. Yet, many questions remain regarding the length of therapy and possible use of immunotherapy alone. #ASCO2025

TEDOPAM - maintenance randomised phase 2 vaccine trial #PDAC Induction mFFX- Folfiri vs Folfiri+ OSE2101 (TAAs) ➡️106 pts ➡️met primary endpoint of 12mth OS>50%; ➡️But control arm mOS 17 vs vaccine arm 15mths ➡️highlights benefit maintenance approaches ASCO OncoAlert #ASCO25

Could not agree more. Feeling like a proud mama this morning!! Mark O'Hara Tim Brown, MD MSCE Max Wattenberg Penn Medicine - Abramson Cancer Center #ASCO2025

Last night at the Penn Medicine - Abramson Cancer Center reception! Wonderful representation ASCO #ASCO25 and we had with several faculty, fellows, alumni presenting science that can change practice! Penn Medicine MD Penn Medicine

Thank you everyone who came to our session on pancreatic cancer today. It was an honour to chair this session with such amazing speakers. Thank you ASCO for the opportunity and Kevin Soares and Kim Reiss Binder (Kim Reiss) for creating such a good session together.